Integration Plan being discussed at HQ

Quote

Anonymous

Guest
The buyer of Amylin wants to keep the Amylin sales force. They recognize that Novo is beefing up it's sales force and wants to be able to have the manpower to counter detail.

The "new" owner does not see the value in continuing the contract with InVentiv Synergy contract and definitely does not see the value in continuing the Specialty/Symlin InVentiv contract.

The new company plans to have their sales force fully "integrated" with the Amylin sales force by late spring of 2012 to launch the Bydureon pen. This will give the "new" owner of Amylin time to develop and realign their management team. Having regional and district managers from the "new" company overseeing the Amylin sales force will help facilitate a more fluid transition and give more uniformity to the whole sales force.

This integration plan is what pushed Amyin to announce the retention plan. Even though the "new" owner is only interested in keeping the Amlin sales force and not the Inventive sales force or and Amylin middle management.
 

Anonymous said:
The buyer of Amylin wants to keep the Amylin sales force. They recognize that Novo is beefing up it's sales force and wants to be able to have the manpower to counter detail.

The "new" owner does not see the value in continuing the contract with InVentiv Synergy contract and definitely does not see the value in continuing the Specialty/Symlin InVentiv contract.

The new company plans to have their sales force fully "integrated" with the Amylin sales force by late spring of 2012 to launch the Bydureon pen. This will give the "new" owner of Amylin time to develop and realign their management team. Having regional and district managers from the "new" company overseeing the Amylin sales force will help facilitate a more fluid transition and give more uniformity to the whole sales force.

This integration plan is what pushed Amyin to announce the retention plan. Even though the "new" owner is only interested in keeping the Amlin sales force and not the Inventive sales force or and Amylin middle management.
Click to expand...

late spring of 2012 already passed!
 
Anonymous said:
The buyer of Amylin wants to keep the Amylin sales force. They recognize that Novo is beefing up it's sales force and wants to be able to have the manpower to counter detail.

The "new" owner does not see the value in continuing the contract with InVentiv Synergy contract and definitely does not see the value in continuing the Specialty/Symlin InVentiv contract.

The new company plans to have their sales force fully "integrated" with the Amylin sales force by late spring of 2012 to launch the Bydureon pen. This will give the "new" owner of Amylin time to develop and realign their management team. Having regional and district managers from the "new" company overseeing the Amylin sales force will help facilitate a more fluid transition and give more uniformity to the whole sales force.

This integration plan is what pushed Amyin to announce the retention plan. Even though the "new" owner is only interested in keeping the Amlin sales force and not the Inventive sales force or and Amylin middle management.
Click to expand...

I see you know that you don't know anything!
 
Anonymous said:
If you are someone that knows......than WTF are you doing trolling on this board. This board is for people that want to know and want to share. So take your all knowing, smug bullshit elsewhere.

PUT UP or SHUT THE FUCK UP.

Have a nice day.
Click to expand...

Well said. I can't stand the drop in posters with their smug, pseudo in the know bullchit
If you know something and made the effort to post then spill it or beat it
 
Anonymous said:
The buyer of Amylin wants to keep the Amylin sales force. They recognize that Novo is beefing up it's sales force and wants to be able to have the manpower to counter detail.

The "new" owner does not see the value in continuing the contract with InVentiv Synergy contract and definitely does not see the value in continuing the Specialty/Symlin InVentiv contract.

The new company plans to have their sales force fully "integrated" with the Amylin sales force by late spring of 2012 to launch the Bydureon pen. This will give the "new" owner of Amylin time to develop and realign their management team. Having regional and district managers from the "new" company overseeing the Amylin sales force will help facilitate a more fluid transition and give more uniformity to the whole sales force.

This integration plan is what pushed Amyin to announce the retention plan. Even though the "new" owner is only interested in keeping the Amlin sales force and not the Inventive sales force or and Amylin middle management.
Click to expand...


There could be some accuracy to this. When Sanofi,bought Genzyme, they kept the reps but favored a management team that was made up of Sanofi people.
 
Anonymous said:
The buyer of Amylin wants to keep the Amylin sales force. They recognize that Novo is beefing up it's sales force and wants to be able to have the manpower to counter detail.

The "new" owner does not see the value in continuing the contract with InVentiv Synergy contract and definitely does not see the value in continuing the Specialty/Symlin InVentiv contract.

The new company plans to have their sales force fully "integrated" with the Amylin sales force by late spring of 2012 to launch the Bydureon pen. This will give the "new" owner of Amylin time to develop and realign their management team. Having regional and district managers from the "new" company overseeing the Amylin sales force will help facilitate a more fluid transition and give more uniformity to the whole sales force.

This integration plan is what pushed Amyin to announce the retention plan. Even though the "new" owner is only interested in keeping the Amlin sales force and not the Inventive sales force or and Amylin middle management.
Click to expand...

That would be fine if the legacy reps were good sales people. If you retain the Amylin sales force all you are doing is polishing a turd. They need to give the OLD sales force the door because they can't move business, like not turning a profit in years. For some odd reason someone feels sorry for them, like the retarded kid in the corner.
 
Anonymous said:
That would be fine if the legacy reps were good sales people. If you retain the Amylin sales force all you are doing is polishing a turd. They need to give the OLD sales force the door because they can't move business, like not turning a profit in years. For some odd reason someone feels sorry for them, like the retarded kid in the corner.
Click to expand...

Great response. If the sales people are Turds, how would you define the management.?
 
Anonymous said:
There could be some accuracy to this. When Sanofi,bought Genzyme, they kept the reps but favored a management team that was made up of Sanofi people.
Click to expand...

From a Sanofi rep...hahaha! you are so funny. I see you don't know that those reps were gone a year later, they only kept R&D. For the last 4 years (2009-2012) Sanofi has been laying off reps every single year, and they are already planning one for 2013. So you better pick any of the other 6 companies, even Pfizer. If Sanofi buys Amylin off you go, except for R&D!

Educate yourself:
The company has been shedding sales positions for several years as part of a €2 billion cost-cutting exercise, and Sanofi recently said it would slash another €2 billion by the end of 2015. By the end of the year, according to previous company projections, Sanofi's US sales force will be around 4,500 – less than half of what it was in 2008.
 
Anonymous said:
The buyer of Amylin wants to keep the Amylin sales force. They recognize that Novo is beefing up it's sales force and wants to be able to have the manpower to counter detail.

The "new" owner does not see the value in continuing the contract with InVentiv Synergy contract and definitely does not see the value in continuing the Specialty/Symlin InVentiv contract.

The new company plans to have their sales force fully "integrated" with the Amylin sales force by late spring of 2012 to launch the Bydureon pen. This will give the "new" owner of Amylin time to develop and realign their management team. Having regional and district managers from the "new" company overseeing the Amylin sales force will help facilitate a more fluid transition and give more uniformity to the whole sales force.

This integration plan is what pushed Amyin to announce the retention plan. Even though the "new" owner is only interested in keeping the Amlin sales force and not the Inventive sales force or and Amylin middle management.
Click to expand...

What a fucking moron!
 
Anonymous said:
Why does Sanofi want keep R&D of Amln?
Click to expand...

Because our R & D leadership (so called) is piece of shit and filled with politicians rather than scientist. And my friends we need more politicians since this is election year.
 
Anonymous said:
The buyer of Amylin wants to keep the Amylin sales force. They recognize that Novo is beefing up it's sales force and wants to be able to have the manpower to counter detail.

The "new" owner does not see the value in continuing the contract with InVentiv Synergy contract and definitely does not see the value in continuing the Specialty/Symlin InVentiv contract.

The new company plans to have their sales force fully "integrated" with the Amylin sales force by late spring of 2012 to launch the Bydureon pen. This will give the "new" owner of Amylin time to develop and realign their management team. Having regional and district managers from the "new" company overseeing the Amylin sales force will help facilitate a more fluid transition and give more uniformity to the whole sales force.

This integration plan is what pushed Amyin to announce the retention plan. Even though the "new" owner is only interested in keeping the Amlin sales force and not the Inventive sales force or and Amylin middle management.
Click to expand...

Heard the word integration used a lot today-any truth to this post?
 


Write your reply...
Top Bottom
Back
Quote